Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease
NCT ID: NCT02952131
Last Updated: 2024-10-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
SUSPENDED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-11-30
Study Completion Date
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Inflammatory Bowel Disease (IBD) is a group of inflammatory conditions of the small bowel and colon. Main types include Ulcerative Colitis and Crohn's Disease. Symptoms are often difficult to distinguish except for location and nature of changes. IBD complex arises with interaction of environmental, genetic factors, immunological responses, and chronic and recurring inflammation.
Many factor appear as contributory, but no single set of issues appear to explain the process. Microbiota, intestinal wall granulation or breach, dietary, genetic predisposition all appear to factors. Treatment is often reactive or suppressive medications, neither of which appears to reverse the disease processes. This study explores the value of a complex group of adipose-derived stem/stromal cells (AD-cSVF) in the disease process.
Many factor appear as contributory, but no single set of issues appear to explain the process. Microbiota, intestinal wall granulation or breach, dietary, genetic predisposition all appear to factors. Treatment is often reactive or suppressive medications, neither of which appears to reverse the disease processes. This study explores the value of a complex group of adipose-derived stem/stromal cells (AD-cSVF) in the disease process.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease
NCT00278577
CROHN'S DISEASE
TERMINATED
PHASE1
Treatment of Perianal Disease Using Adipose-derived Stem Cells
NCT03913572
Perianal Fistula
Crohn Disease
UNKNOWN
High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)
NCT05587673
Inflammatory Bowel Diseases
Crohn Disease
Ulcerative Colitis
+1 more
COMPLETED
PHASE1
Immune Ablation and Stem Cell Support for Crohn's Disease
NCT00179842
Crohn Disease
WITHDRAWN
PHASE2
Biomarker-based Multidisciplinary Team (Bio-MDT) Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease
NCT04082559
Inflammatory Bowel Diseases
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
IBD often presents clinically as abdominal pain, diarrhea (with and without blood), fever, weight loss, failure to thrive, and many related symptoms. Complications of the disorders may also include anemia, skin rashes, arthritis, severe chronic fatigue, and eye inflammatory changes.
It is felt that IBD disorders may be caused by combination of environmental, immune, genetic, and bacterial factors. Results of these issues produce a chronic inflammatory disorder, in which the immune system attacks the gastrointestinal tract, perhaps directed by certain microbial antigens. The group appears not to be a pure autoimmune disease reaction, but may relate to a immunodeficiency state.
There are no medications or surgical procedures that are known to cure the diseases. Most are aimed at reduction of symptoms, maintain remissions, and try to prevent relapses. Temporary anti-inflammatory medications may improve the acute process, followed by methotrexate or thiopurine to maintain remission states. Surgery appears important in cases of perforation, abscesses, obstructions, or cancer management.
Actual occurrence is unknown, as there are more than Crohn's Disease and Ulcerative Colitis which appear related. It is estimated that more than 35,000 deaths were reported in 2010. Crohn's Disease alone appears to affect 3.2 per 1000 people in Europe and North America alone.
The usual onset of symptoms may appear before actual diagnoses are made, with typical diagnoses occurring between 15-30 years of age. Lead by abdominal pain symptoms (usually lower right quadrant) and the recurrent periods of flare and remission. Many dietary, bacterial, antimicrobials, and environmental factors receive attention, some new interest in evaluating alternative therapeutic modalities to deal of issues of immune system. Use of the immune privileged cellular agents held within the AD-cSVF is proposed to help with the inflammatory contributors as well as the modulation of inflammation which favors chronic wound healing and avascular systems. Known to provide secretory antibiotic (ll-37) contributions, some thought of pro- and anti-microbials, may prove of value in those areas specifically. Cytokine and growth factors implications at the lesion sites remain to be poorly understood, but those experienced in biocellular regenerative therapies have experienced contributions to healing and prevention of recurrences of ulcerative skin lesions.
Harvest of autologous of adipose-derived tissue stromal vascular fraction (AD-tSVF) is a proven rich resource of microvascular stem/stromal cell elements with well documented growth factor and cytokine contributors. With the advent of safe, measurable, and efficacious and reproducible numbers in a closed isolation environment, the ability to isolate and concentrate a cell-only product. This AD-cSVF is capable of reintroduction into patients, via a Normal Saline Solution, via parenteral route.
This study is intended to evaluate the safety (adverse outcomes) and efficacy of using autologous cellular therapy in cases of IBD.
It is felt that IBD disorders may be caused by combination of environmental, immune, genetic, and bacterial factors. Results of these issues produce a chronic inflammatory disorder, in which the immune system attacks the gastrointestinal tract, perhaps directed by certain microbial antigens. The group appears not to be a pure autoimmune disease reaction, but may relate to a immunodeficiency state.
There are no medications or surgical procedures that are known to cure the diseases. Most are aimed at reduction of symptoms, maintain remissions, and try to prevent relapses. Temporary anti-inflammatory medications may improve the acute process, followed by methotrexate or thiopurine to maintain remission states. Surgery appears important in cases of perforation, abscesses, obstructions, or cancer management.
Actual occurrence is unknown, as there are more than Crohn's Disease and Ulcerative Colitis which appear related. It is estimated that more than 35,000 deaths were reported in 2010. Crohn's Disease alone appears to affect 3.2 per 1000 people in Europe and North America alone.
The usual onset of symptoms may appear before actual diagnoses are made, with typical diagnoses occurring between 15-30 years of age. Lead by abdominal pain symptoms (usually lower right quadrant) and the recurrent periods of flare and remission. Many dietary, bacterial, antimicrobials, and environmental factors receive attention, some new interest in evaluating alternative therapeutic modalities to deal of issues of immune system. Use of the immune privileged cellular agents held within the AD-cSVF is proposed to help with the inflammatory contributors as well as the modulation of inflammation which favors chronic wound healing and avascular systems. Known to provide secretory antibiotic (ll-37) contributions, some thought of pro- and anti-microbials, may prove of value in those areas specifically. Cytokine and growth factors implications at the lesion sites remain to be poorly understood, but those experienced in biocellular regenerative therapies have experienced contributions to healing and prevention of recurrences of ulcerative skin lesions.
Harvest of autologous of adipose-derived tissue stromal vascular fraction (AD-tSVF) is a proven rich resource of microvascular stem/stromal cell elements with well documented growth factor and cytokine contributors. With the advent of safe, measurable, and efficacious and reproducible numbers in a closed isolation environment, the ability to isolate and concentrate a cell-only product. This AD-cSVF is capable of reintroduction into patients, via a Normal Saline Solution, via parenteral route.
This study is intended to evaluate the safety (adverse outcomes) and efficacy of using autologous cellular therapy in cases of IBD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Inflammatory Bowel Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lipoaspiration Arm 1
Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
Group Type
EXPERIMENTAL
Lipoaspiration
Intervention Type
PROCEDURE
Closed Syringe Harvesting Autologous Subdermal Fat
AD-cSVF Arm 2
Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
Group Type
EXPERIMENTAL
AD-cSVF
Intervention Type
PROCEDURE
Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
Normal Saline IV Arm 3
Normal Saline IV with AD-cSVF cells
Group Type
EXPERIMENTAL
Normal Saline IV
Intervention Type
PROCEDURE
Normal Saline IV containing AD-cSVF
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lipoaspiration
Closed Syringe Harvesting Autologous Subdermal Fat
Intervention Type
PROCEDURE
AD-cSVF
Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
Intervention Type
PROCEDURE
Normal Saline IV
Normal Saline IV containing AD-cSVF
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients, either sex 18 years and older with confirmed diagnosis of IBD
* Patients, either sex younger than 18 years upon approval of responsible parties and agreement of investigators
* Ability of patient to provide informed consent (or legal guardian)
* IBD diagnosed at least 6 months earlier to therapy using usual criteria
* Negative pregnancy test for women of childbearing age (menarche to menopause)
* Patients, either sex younger than 18 years upon approval of responsible parties and agreement of investigators
* Ability of patient to provide informed consent (or legal guardian)
* IBD diagnosed at least 6 months earlier to therapy using usual criteria
* Negative pregnancy test for women of childbearing age (menarche to menopause)
Exclusion Criteria
* Mental incapacity that prevents adequate understanding of study and associate procedures and providing informed consent
* Severe IBD preventing tolerance of procedures needed
* Patients with impaired systemic condition, according to investigator judgment, needs immediate corticosteroid or surgical intervention
* Patients that fulfill criteria of cortico-dependency and in current treatment with corticosteroids
* Patients with history of colectomy
* Known history of alcohol, smoking dependence or additive substance abuse
* History related malignant disease - including patients participating in clinical trial with investigational drug within 6 months
* Patients with known history of allergies to any substance used in this protocol
* Pregnant or breastfeeding females
* Presence of severe concomitant disease, in investigators opinion threatens patient's well being or safety
* Severe IBD preventing tolerance of procedures needed
* Patients with impaired systemic condition, according to investigator judgment, needs immediate corticosteroid or surgical intervention
* Patients that fulfill criteria of cortico-dependency and in current treatment with corticosteroids
* Patients with history of colectomy
* Known history of alcohol, smoking dependence or additive substance abuse
* History related malignant disease - including patients participating in clinical trial with investigational drug within 6 months
* Patients with known history of allergies to any substance used in this protocol
* Pregnant or breastfeeding females
* Presence of severe concomitant disease, in investigators opinion threatens patient's well being or safety
Minimum Eligible Age
18 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Terry, Glenn C., M.D.
INDIV
Sponsor Role
collaborator
Healeon Medical Inc
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert W. Alexander, MD, FICS
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert W Alexander, MD
Role: PRINCIPAL_INVESTIGATOR
Healeon Medical Inc
Glenn C Terry, MD
Role: STUDY_DIRECTOR
Global Alliance for Regenerative Medicine (GARM)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regenevita LLC
Stevensville, Montana, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May 12;369(9573):1627-40. doi: 10.1016/S0140-6736(07)60750-8.
Reference Type
BACKGROUND
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12;369(9573):1641-57. doi: 10.1016/S0140-6736(07)60751-X.
Reference Type
BACKGROUND
Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol. 2014 Mar 28;20(12):3231-44. doi: 10.3748/wjg.v20.i12.3231.
Reference Type
BACKGROUND
Wang GF, Ren JA, Liu S, Chen J, Gu GS, Wang XB, Fan CG, Li JS. Clinical characteristics of non-perianal fistulating Crohn's disease in China: a single-center experience of 184 cases. Chin Med J (Engl). 2012 Jul;125(14):2405-10.
Reference Type
BACKGROUND
Mahadeva U, Martin JP, Patel NK, Price AB. Granulomatous ulcerative colitis: a re-appraisal of the mucosal granuloma in the distinction of Crohn's disease from ulcerative colitis. Histopathology. 2002 Jul;41(1):50-5. doi: 10.1046/j.1365-2559.2002.01416.x.
Reference Type
BACKGROUND
Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013 Jan;29(1):79-84. doi: 10.1097/MOG.0b013e32835a4b3e.
Reference Type
BACKGROUND
Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011 Jun 15;474(7351):298-306. doi: 10.1038/nature10208.
Reference Type
BACKGROUND
Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010 Sep;16(9):1583-97. doi: 10.1002/ibd.21282.
Reference Type
BACKGROUND
Coskun M. Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne). 2014 Aug 25;1:24. doi: 10.3389/fmed.2014.00024. eCollection 2014.
Reference Type
BACKGROUND
Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis. 2010 Feb 15;50(4):473-80. doi: 10.1086/649923.
Reference Type
BACKGROUND
Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011 May;60(5):571-607. doi: 10.1136/gut.2010.224154.
Reference Type
BACKGROUND
Charlebois A, Rosenfeld G, Bressler B. The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: A Systematic Review. Crit Rev Food Sci Nutr. 2016 Jun 10;56(8):1370-8. doi: 10.1080/10408398.2012.760515.
Reference Type
BACKGROUND
Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014 Dec;8(12):1569-81. doi: 10.1016/j.crohns.2014.08.006. Epub 2014 Sep 13.
Reference Type
BACKGROUND
Gilardi D, Fiorino G, Genua M, Allocca M, Danese S. Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):835-46. doi: 10.1586/17474124.2014.917954. Epub 2014 May 12.
Reference Type
BACKGROUND
Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, Korzenik J. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis. 2015 Jan;9(1):86-106. doi: 10.1093/ecco-jcc/jju007. Epub 2014 Nov 28.
Reference Type
BACKGROUND
Dave M, Mehta K, Luther J, Baruah A, Dietz AB, Faubion WA Jr. Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov;21(11):2696-707. doi: 10.1097/MIB.0000000000000543.
Reference Type
BACKGROUND
Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014 Dec 9;7:473-87. doi: 10.2147/CEG.S27530. eCollection 2014.
Reference Type
BACKGROUND
Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology. 2012 Feb;20(1):1-18. doi: 10.1007/s10787-011-0104-6. Epub 2011 Dec 20.
Reference Type
BACKGROUND
Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association Between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov;21(11):2708-17. doi: 10.1097/MIB.0000000000000546.
Reference Type
BACKGROUND
Dessein R, Chamaillard M, Danese S. Innate immunity in Crohn's disease: the reverse side of the medal. J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S144-7. doi: 10.1097/MCG.0b013e3181662c90.
Reference Type
BACKGROUND
Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010 Feb;38(1):20-31. doi: 10.1007/s12016-009-8133-2.
Reference Type
BACKGROUND
Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med. 2009 Aug 31;206(9):1839-43. doi: 10.1084/jem.20091683. Epub 2009 Aug 17.
Reference Type
BACKGROUND
Lalande JD, Behr MA. Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation. Expert Rev Clin Immunol. 2010 Jul;6(4):633-41. doi: 10.1586/eci.10.29.
Reference Type
BACKGROUND
Yamamoto-Furusho JK, Korzenik JR. Crohn's disease: innate immunodeficiency? World J Gastroenterol. 2006 Nov 14;12(42):6751-5. doi: 10.3748/wjg.v12.i42.6751.
Reference Type
BACKGROUND
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001. Epub 2011 Oct 14.
Reference Type
BACKGROUND
Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012 Dec 24;72(18):2333-49. doi: 10.2165/11638120-000000000-00000.
Reference Type
BACKGROUND
Braat H, Peppelenbosch MP, Hommes DW. Immunology of Crohn's disease. Ann N Y Acad Sci. 2006 Aug;1072:135-54. doi: 10.1196/annals.1326.039.
Reference Type
BACKGROUND
Henckaerts L, Figueroa C, Vermeire S, Sans M. The role of genetics in inflammatory bowel disease. Curr Drug Targets. 2008 May;9(5):361-8. doi: 10.2174/138945008784221161.
Reference Type
BACKGROUND
Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet. 2006 Feb 25;367(9511):668-78. doi: 10.1016/S0140-6736(06)68265-2.
Reference Type
BACKGROUND
Clevers H. Inflammatory bowel disease, stress, and the endoplasmic reticulum. N Engl J Med. 2009 Feb 12;360(7):726-7. doi: 10.1056/NEJMcibr0809591. No abstract available.
Reference Type
BACKGROUND
Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007 Jun;132(7):2359-70. doi: 10.1053/j.gastro.2007.03.104. Epub 2007 Apr 13.
Reference Type
BACKGROUND
Naser SA, Sagramsingh SR, Naser AS, Thanigachalam S. Mycobacterium avium subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel disease patients. World J Gastroenterol. 2014 Jun 21;20(23):7403-15. doi: 10.3748/wjg.v20.i23.7403.
Reference Type
BACKGROUND
Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007 Mar;117(3):636-47. doi: 10.1172/JCI29255. Epub 2007 Feb 15.
Reference Type
BACKGROUND
Hara AK, Leighton JA, Heigh RI, Sharma VK, Silva AC, De Petris G, Hentz JG, Fleischer DE. Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. Radiology. 2006 Jan;238(1):128-34. doi: 10.1148/radiol.2381050296.
Reference Type
BACKGROUND
Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006 Feb;26(1):31-41. doi: 10.1055/s-2006-933561.
Reference Type
BACKGROUND
Kristo I, Stift A, Bergmann M, Riss S. Surgical recurrence in Crohn's disease: Are we getting better? World J Gastroenterol. 2015 May 28;21(20):6097-100. doi: 10.3748/wjg.v21.i20.6097.
Reference Type
BACKGROUND
Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, Hahn EG, Schuppan D. Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion. 2004;69(3):131-9. doi: 10.1159/000078151. Epub 2004 Apr 26.
Reference Type
BACKGROUND
Smart HL, Mayberry JF, Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut. 1986 Jul;27(7):826-8. doi: 10.1136/gut.27.7.826.
Reference Type
BACKGROUND
Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016 May 28;22(20):4794-801. doi: 10.3748/wjg.v22.i20.4794.
Reference Type
BACKGROUND
Walker MM, Murray JA. An update in the diagnosis of coeliac disease. Histopathology. 2011 Aug;59(2):166-79. doi: 10.1111/j.1365-2559.2010.03680.x. Epub 2010 Nov 3.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RGV-GARM3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment
NCT01932658
WITHDRAWN
EARLY_PHASE1
Diet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis
NCT07168499
RECRUITING
NA
Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease
NCT05521672
TERMINATED
PHASE1/PHASE2
Autologous Stem Cell Transplant for Refractory Crohn's Disease
NCT02676622
WITHDRAWN
PHASE2
Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease
NCT04519697
UNKNOWN
PHASE1/PHASE2
Crohn's Disease Stem Cell Transplantation
NCT00271947
TERMINATED
PHASE2
Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis
NCT01914887
UNKNOWN
PHASE1/PHASE2
Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease
NCT04519671
UNKNOWN
PHASE1/PHASE2
Study for the Treatment of Crohn's Disease With Adacolumn
NCT00162942
COMPLETED
PHASE3
Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula
NCT01314092
TERMINATED
PHASE2
Stem Cell Transplantation in Crohn's Disease
NCT04224558
RECRUITING
PHASE1/PHASE2
Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease
NCT00294112
COMPLETED
PHASE2
Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease
NCT01378390
TERMINATED
PHASE3
90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients
NCT05686135
WITHDRAWN
NA
Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease
NCT04519684
UNKNOWN
PHASE1/PHASE2
Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis
NCT03609905
UNKNOWN
PHASE1/PHASE2
Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease
NCT00586352
COMPLETED
NA
Autologous Adipose-derived Stem Cells (ASCs) for the Treatment of Perianal Fistula in Crohn Disease: A Pilot Study
NCT02403232
UNKNOWN
PHASE2
Collection of Specimens for Study of Inflammatory Bowel Disease
NCT00086554
COMPLETED
ASTIC Autologous Stem Cell Transplantation for Crohn's Disease
NCT00297193
TERMINATED
PHASE3
The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis
NCT00805285
TERMINATED
PHASE2
Inflammatory Bowel Disease(IBD), Treatment Response
NCT05350644
TERMINATED
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
NCT01541579
COMPLETED
PHASE3
Fecal Microbiota Transplantation in Pediatric Patients
NCT02108821
COMPLETED
PHASE1
Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)
NCT02463305
WITHDRAWN
EARLY_PHASE1